Type 2 Diabetes: large RCT finds no effect of sitagliptin on the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease (July-15)

This content is available to authorised users only.
Authorised users need to be logged in to read this content.

NPC Archive Item: What are the DVLA blood glucose monitoring requirements for people with diabetes?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 19th March 2012 This Rapid Review aims to clarify the DVLA requirements and advice for the monitoring of blood glucose in people with diabetes. It is based on the […]

NPC Archive Item: Insulin analogues cost NHS millions

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24 October 2011 A UK study found that if all analogue insulin dispensed in the UK between 2000 and 2009 had been for human insulin alternatives, the NHS would […]

NPC Archive Item: Changes to DVLA rules about driving lorries and buses for insulin-treated people with diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 19 October 2011 From a date to be announced in October 2011, DVLA rules are changing to allow people with insulin-treated diabetes to apply for a group 2 vehicle […]

NPC Archive Item: Cochrane review suggests cautious approach when reducing blood glucose in type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 September 2011 A Cochrane review of 20 randomised controlled trials (RCTs) found that intensive blood glucose control did not significantly reduce all-cause mortality or cardiovascular (CV) mortality, compared […]

NPC Archive Item: No significant benefits for early detection and intensive multifactorial management of type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 12 August 2011 The ADDITION-Europe study looked at the effect of early intensive multifactorial management (of HbA1c, blood pressure, cholesterol; and prescription of aspirin) on 5-year cardiovascular outcomes in […]

NPC Archive Item: Glitazone use associated with pneumonia in a meta-analysis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 16 June 2011 This meta-analysis of 13 RCTs (n=17,627) found the use of glitazones was associated with an increased risk of pneumonia or lower respiratory tract infection (LRTI) in […]

NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]

NPC Archive Item: More evidence for self-monitoring of blood glucose in type 2 diabetes?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22nd February 2011 A study has found that a structured self-monitoring of blood glucose intervention package improved glycaemic control compared with enhanced usual care in patients with poorly controlled type […]

NPC Archive Item: Is pioglitazone▼ associated with an increased cardiovascular risk similar to rosiglitazone?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 16 December 2010 Rosiglitazone was withdrawn from clinical use across Europe because of concerns over excess cardiovascular (CV) risk. This cohort study found that pioglitazone▼ was associated with the […]